• 1

    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277300.

  • 2

    Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age. J Natl Cancer Inst 2008;100:11841187.

    • Search Google Scholar
    • Export Citation
  • 3

    Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998–2003. Int J Cancer 2008;123:14221428.

    • Search Google Scholar
    • Export Citation
  • 4

    Bosetti C, Levi F, Ferlay J. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 2008;122:11181129.

  • 5

    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:21372150.

    • Search Google Scholar
    • Export Citation
  • 6

    Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001;30:14151425.

    • Search Google Scholar
    • Export Citation
  • 7

    Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg 2003;76:S13671369.

  • 8

    Siewert JR, Katja O. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007;17:3844.

  • 9

    Siewert JR, Stein HJ, Feith M. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234:360367.

    • Search Google Scholar
    • Export Citation
  • 10

    Freedman ND, Abnet CC, Leitzmann MF. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007;165:14241433.

    • Search Google Scholar
    • Export Citation
  • 11

    Engel LS, Chow WH, Vaughan TL. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:14041413.

  • 12

    Lagergren J, Bergstrom R, Lindgren A, Nyren O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000;85:340346.

    • Search Google Scholar
    • Export Citation
  • 13

    Gammon M, Schoenberg J, Ahsan H. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997;89:12771284.

    • Search Google Scholar
    • Export Citation
  • 14

    Cook MB, Kamangar F, Whiteman DC. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international beacon consortium. J Natl Cancer Inst 2010;102:13441353.

    • Search Google Scholar
    • Export Citation
  • 15

    Chow WH, Blot WJ, Vaughan TL. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150155.

    • Search Google Scholar
    • Export Citation
  • 16

    Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:8592.

    • Search Google Scholar
    • Export Citation
  • 17

    Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883890.

    • Search Google Scholar
    • Export Citation
  • 18

    Morris Brown L, Swanson CA, Gridley G. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995;87:104109.

  • 19

    Chow WH, Finkle WD, McLaughlin JK. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474477.

    • Search Google Scholar
    • Export Citation
  • 20

    Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825831.

    • Search Google Scholar
    • Export Citation
  • 21

    Cossentino MJ, Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis 2003;14:128135.

  • 22

    Cameron AJ, Romero Y. Symptomatic gastro-oesophageal reflux as a risk factor for oesophageal adenocarcinoma. Gut 2000;46:754755.

  • 23

    Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009;361:25482556.

  • 24

    Anandasabapathy S, Jhamb J, Davila M. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer 2007;109:668674.

    • Search Google Scholar
    • Export Citation
  • 25

    Gopal DV, Lieberman DA, Magaret N. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci 2003;48:15371541.

    • Search Google Scholar
    • Export Citation
  • 26

    Das A, Thomas S, Zablotska LB. Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol 2006;40:405411.

    • Search Google Scholar
    • Export Citation
  • 27

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.

  • 28

    Rice TW, Rusch VW, Apperson-Hansen C. Worldwide esophageal cancer collaboration. Dis Esophagus 2009;22:18.

  • 29

    Kim TJ, Kim HY, Lee KW, Kim MS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics 2009;29:403421.

    • Search Google Scholar
    • Export Citation
  • 30

    Siewert JR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. Dis Esophagus 1996;9:173182.

    • Search Google Scholar
    • Export Citation
  • 31

    Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353361.

    • Search Google Scholar
    • Export Citation
  • 32

    Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788797.

    • Search Google Scholar
    • Export Citation
  • 33

    Ancona E, Ruol A, Santi S. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:21652174.

    • Search Google Scholar
    • Export Citation
  • 34

    Rohatgi PR, Swisher SG, Correa AM. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005;104:13491355.

    • Search Google Scholar
    • Export Citation
  • 35

    Schneider PM, Baldus SE, Metzger R. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005;242:684692.

    • Search Google Scholar
    • Export Citation
  • 36

    Brucher BL, Becker K, Lordick F. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006;106:21192127.

    • Search Google Scholar
    • Export Citation
  • 37

    Langer R, Ott K, Feith M. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 2009;22:15551563.

    • Search Google Scholar
    • Export Citation
  • 38

    Meredith KL, Weber JM, Turaga KK. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol 2010;17:11591167.

    • Search Google Scholar
    • Export Citation
  • 39

    Chirieac LR, Swisher SG, Ajani JA. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005;103:13471355.

    • Search Google Scholar
    • Export Citation
  • 40

    Mandard AM, Dalibard F, Mandard JC. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:26802686.

    • Search Google Scholar
    • Export Citation
  • 41

    Wu TT, Chirieac LR, Abraham SC. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 2007;31:5864.

    • Search Google Scholar
    • Export Citation
  • 42

    Dreilich M, Wanders A, Brattstrom D. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006;19:224231.

    • Search Google Scholar
    • Export Citation
  • 43

    Reichelt U, Duesedau P, Tsourlakis MC. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120129.

    • Search Google Scholar
    • Export Citation
  • 44

    Schoppmann SF, Jesch B, Friedrich J. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol 2010;34:18681873.

  • 45

    Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int 2011;2010:674182.

    • Search Google Scholar
    • Export Citation
  • 46

    Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:15231529.

  • 47

    Tanner M, Hollmen M, Junttila TT. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273278.

    • Search Google Scholar
    • Export Citation
  • 48

    Bang Y, Chung H, Xu J. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 4556.

    • Search Google Scholar
    • Export Citation
  • 49

    Bang YJ, Van Cutsem E, Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687697.

    • Search Google Scholar
    • Export Citation
  • 50

    Hofmann M, Stoss O, Shi D. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797805.

    • Search Google Scholar
    • Export Citation
  • 51

    Cunningham D, Allum WH, Stenning SP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:1120.

    • Search Google Scholar
    • Export Citation
  • 52

    Tepper J, Krasna MJ, Niedzwiecki D. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:10861092.

    • Search Google Scholar
    • Export Citation
  • 53

    Aloia TA, Harpole DH, Reed CE. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001;72:859866.

    • Search Google Scholar
    • Export Citation
  • 54

    Luthra R, Wu TT, Luthra MG. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006;24:259267.

    • Search Google Scholar
    • Export Citation
  • 55

    McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64:15611569.

  • 56

    Ng T, Vezeridis MP. Advances in the surgical treatment of esophageal cancer. J Surg Oncol 2010;101:725729.

  • 57

    Walther B, Johansson J, Johnsson F. Cervical or thoracic anastomosis after esophageal resection and gastric tube reconstruction: a prospective randomized trial comparing sutured neck anastomosis with stapled intrathoracic anastomosis. Ann Surg 2003;238:803812.

    • Search Google Scholar
    • Export Citation
  • 58

    Urschel JD, Blewett CJ, Bennett WF. Handsewn or stapled esophagogastric anastomoses after esophagectomy for cancer: meta-analysis of randomized controlled trials. Dis Esophagus 2001;14:212217.

    • Search Google Scholar
    • Export Citation
  • 59

    Klink CD, Binnebosel M, Schneider M. Operative outcome of colon interposition in the treatment of esophageal cancer: a 20-year experience. Surgery 2010;147:491496.

    • Search Google Scholar
    • Export Citation
  • 60

    Visbal AL, Allen MS, Miller DL. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2001;71:18031808.

  • 61

    Orringer MB, Marshall B, Chang AC. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg 2007;246:363372.

  • 62

    Hulscher JBF, van Sandick JW, de Boer AG. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:16621669.

    • Search Google Scholar
    • Export Citation
  • 63

    Chang AC, Ji H, Birkmeyer NJ. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg 2008;85:424429.

  • 64

    Forshaw MJ, Gossage JA, Ockrim J. Left thoracoabdominal esophagogastrectomy: still a valid operation for carcinoma of the distal esophagus and esophagogastric junction. Dis Esophagus 2006;19:340345.

    • Search Google Scholar
    • Export Citation
  • 65

    Luketich JD, Alvelo-Rivera M, Buenaventura PO. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003;238:486494.

  • 66

    Zingg U, McQuinn A, DiValentino D. Minimally invasive versus open esophagectomy for patients with esophageal cancer. Ann Thorac Surg 2009;87:911919.

    • Search Google Scholar
    • Export Citation
  • 67

    Decker G, Coosemans W, De Leyn P. Minimally invasive esophagectomy for cancer. Eur J Cardiothorac Surg 2009;35:1320.

  • 68

    Levy RM, Wizorek J, Shende M, Luketich JD. Laparoscopic and thoracoscopic esophagectomy. Adv Surg 2010;44:101116.

  • 69

    Perry Y, Fernando HC, Buenaventura PO. Minimally invasive esophagectomy in the elderly. JSLS 2002;6:299304.

  • 70

    Birkmeyer JD, Siewers AE, Finlayson EV. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:11281137.

  • 71

    Steyerberg EW, Neville BA, Koppert LB. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006;24:42774284.

    • Search Google Scholar
    • Export Citation
  • 72

    Swisher SG, Wynn P, Putnam JB. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 2002;123:175183.

    • Search Google Scholar
    • Export Citation
  • 73

    Krasna MJ, Reed CE, Jaklitsch MT. Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons. Ann Thorac Surg 1995;60:13371340.

    • Search Google Scholar
    • Export Citation
  • 74

    Hofstetter WL. Lymph node dissection in esophageal cancer. In: Yang SC, Cameron DE, eds. Current Therapy in Thoracic and Cardiovascular Surgery. Philadelphia, PA: Mosby, Inc; 2004:360363.

    • Search Google Scholar
    • Export Citation
  • 75

    Groth SS, Whitson BA, Li Z. Determination of the ideal number of lymph nodes to examine to optimize survival in patients with esophageal carcinoma: data from the surveillance epidemiology and end results database [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4528.

    • Search Google Scholar
    • Export Citation
  • 76

    Peyre CG, Hagen JA, DeMeester SR. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008;248:979985.

    • Search Google Scholar
    • Export Citation
  • 77

    Rizk NP, Ishwaran H, Rice TW. Optimum lymphadenectomy for esophageal cancer. Ann Surg 2010;251:4650.

  • 78

    Fujita H, Sueyoshi S, Yamana H. Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg 2001;25:424431.

    • Search Google Scholar
    • Export Citation
  • 79

    Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol 2005;23:44904498.

    • Search Google Scholar
    • Export Citation
  • 80

    Conio M, Repici A, Cestari R. Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol 2005;11:66506655.

    • Search Google Scholar
    • Export Citation
  • 81

    Ell C, May A, Gossner L. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000;118:670677.

    • Search Google Scholar
    • Export Citation
  • 82

    Seewald S, Akaraviputh T, Seitz U. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003;57:854859.

    • Search Google Scholar
    • Export Citation
  • 83

    Larghi A, Lightdale CJ, Ross AS. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy 2007;39:10861091.

    • Search Google Scholar
    • Export Citation
  • 84

    Lopes CV, Hela M, Pesenti C. Circumferential endoscopic resection of Barrett's esophagus with high-grade dysplasia or early adenocarcinoma. Surg Endosc 2007;21:820824.

    • Search Google Scholar
    • Export Citation
  • 85

    Chennat J, Konda VJ, Ross AS. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma—an American single-center experience. Am J Gastroenterol 2009;104:26842692.

    • Search Google Scholar
    • Export Citation
  • 86

    Ganz RA, Overholt BF, Sharma VK. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc 2008;68:3540.

    • Search Google Scholar
    • Export Citation
  • 87

    Maish MS, DeMeester SR. Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma. Ann Thorac Surg 2004;78:17771782.

    • Search Google Scholar
    • Export Citation
  • 88

    Overholt BF, Lightdale CJ, Wang KK. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488498.

    • Search Google Scholar
    • Export Citation
  • 89

    Pech O, Gossner L, May A. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005;62:2430.

    • Search Google Scholar
    • Export Citation
  • 90

    Shaheen NJ, Sharma P, Overholt BF. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:22772288.

  • 91

    Dumot JA, Vargo JJ II, Falk GW. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009;70:635644.

    • Search Google Scholar
    • Export Citation
  • 92

    Shaheen NJ, Greenwald BD, Peery AF. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010;71:680685.

    • Search Google Scholar
    • Export Citation
  • 93

    Pech O, Behrens A, May A. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:12001206.

    • Search Google Scholar
    • Export Citation
  • 94

    Komanduri S, Swanson G, Keefer L, Jakate S. Use of a new jumbo forceps improves tissue acquisition of Barrett's esophagus surveillance biopsies. Gastrointest Endosc 2009;70:10721078.

    • Search Google Scholar
    • Export Citation
  • 95

    Gaur P, Sepesi B, Hofstetter WL. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer 2011;117:6369.

    • Search Google Scholar
    • Export Citation
  • 96

    Larghi A, Lightdale CJ, Memeo L. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc 2005;62:1623.

    • Search Google Scholar
    • Export Citation
  • 97

    Thomas T, Singh R, Ragunath K. Trimodal imaging-assisted endoscopic mucosal resection of early Barrett's neoplasia. Surg Endosc 2009;23:16091613.

    • Search Google Scholar
    • Export Citation
  • 98

    Mannath J, Subramanian V, Hawkey CJ, Ragunath K. Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett's esophagus: a meta-analysis. Endoscopy 2010;42:351359.

    • Search Google Scholar
    • Export Citation
  • 99

    Anagnostopoulos GK, Yao K, Kaye P. Novel endoscopic observation in Barrett's oesophagus using high resolution magnification endoscopy and narrow band imaging. Aliment Pharmacol Ther 2007;26:501507.

    • Search Google Scholar
    • Export Citation
  • 100

    Barbour AP, Rizk NP, Gerdes H. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. J Am Coll Surg 2007;205:593601.

    • Search Google Scholar
    • Export Citation
  • 101

    Choi J, Kim SG, Kim JS. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 2010;24:13801386.

    • Search Google Scholar
    • Export Citation
  • 102

    Keswani RN, Early DS, Edmundowicz SA. Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. Gastrointest Endosc 2009;69:12101217.

    • Search Google Scholar
    • Export Citation
  • 103

    Bergman JJ. The endoscopic diagnosis and staging of oesophageal adenocarcinoma. Best Pract Res Clin Gastroenterol 2006;20:843866.

  • 104

    Vazquez-Sequeiros E, Norton ID, Clain JE. Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma. Gastrointest Endosc 2001;53:751757.

    • Search Google Scholar
    • Export Citation
  • 105

    Vazquez-Sequeiros E, Wiersema MJ, Clain JE. Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology 2003;125:16261635.

    • Search Google Scholar
    • Export Citation
  • 106

    Lightdale CJ, Heier SK, Marcon NE. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 1995;42:507512.

    • Search Google Scholar
    • Export Citation
  • 107

    Vakil N, Morris AI, Marcon N. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 2001;96:17911796.

    • Search Google Scholar
    • Export Citation
  • 108

    Ribeiro A, Franceschi D, Parra J. Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. Am J Gastroenterol 2006;101:12161221.

    • Search Google Scholar
    • Export Citation
  • 109

    Sarkaria IS, Rizk NP, Bains MS. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 2009;249:764767.

    • Search Google Scholar
    • Export Citation
  • 110

    Lightdale CJ, Botet JF, Kelsen DP. Diagnosis of recurrent upper gastrointestinal cancer at the surgical anastomosis by endoscopic ultrasound. Gastrointest Endosc 1989;35:407412.

    • Search Google Scholar
    • Export Citation
  • 111

    Reid BJ, Levine DS, Longton G. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:16691676.

    • Search Google Scholar
    • Export Citation
  • 112

    Prasad GA, Bansal A, Sharma P, Wang KK. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010;105:14901502.

    • Search Google Scholar
    • Export Citation
  • 113

    Sharma P, Dent J, Armstrong D. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:13921399.

    • Search Google Scholar
    • Export Citation
  • 114

    Chennat J, Waxman I. Endoscopic treatment of Barrett's esophagus: from metaplasia to intramucosal carcinoma. World J Gastroenterol 2010;16:37803785.

    • Search Google Scholar
    • Export Citation
  • 115

    Newaishy GA, Read GA, Duncan W, Kerr GR. Results of radical radiotherapy of squamous cell carcinoma of the oesophagus. Clin Radiol 1982;33:347352.

    • Search Google Scholar
    • Export Citation
  • 116

    Okawa T, Kita M, Tanaka M, Ikeda M. Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1989;17:4954.

    • Search Google Scholar
    • Export Citation
  • 117

    Sun DR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys 1989;16:329334.

    • Search Google Scholar
    • Export Citation
  • 118

    Shi XH, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol 1999;51:2126.

  • 119

    al-Sarraf M, Martz K, Herskovic A. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277284. [Erratum in J Clin Oncol 1997;15:866.]

    • Search Google Scholar
    • Export Citation
  • 120

    Herskovic A, Martz K, al-Sarraf M. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:15931598.

    • Search Google Scholar
    • Export Citation
  • 121

    Hosokawa M, Shirato H, Ohara M. Intraoperative radiation therapy to the upper mediastinum and nerve-sparing three-field lymphadenectomy followed by external beam radiotherapy for patients with thoracic esophageal carcinoma. Cancer 1999;86:613.

    • Search Google Scholar
    • Export Citation
  • 122

    Chandra A, Guerrero TM, Liu HH. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 2005;77:247253.

    • Search Google Scholar
    • Export Citation
  • 123

    Fu WH, Wang LH, Zhou ZM. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. World J Gastroenterol 2004;10:10981102.

    • Search Google Scholar
    • Export Citation
  • 124

    Mayo CS, Urie MM, Fitzgerald TJ. Hybrid IMRT for treatment of cancers of the lung and esophagus. Int J Radiat Oncol Biol Phys 2008;71:14081418.

    • Search Google Scholar
    • Export Citation
  • 125

    Nutting CM, Bedford JL, Cosgrove VP. Intensity-modulated radiotherapy reduces lung irradiation in patients with carcinoma of the oesophagus. Front Radiat Ther Oncol 2002;37:128131.

    • Search Google Scholar
    • Export Citation
  • 126

    Arnott SJ, Duncan W, Kerr GR. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 1992;24:108113.

    • Search Google Scholar
    • Export Citation
  • 127

    Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 1991;173:123130.

    • Search Google Scholar
    • Export Citation
  • 128

    Wang M, Gu XZ, Yin WB. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 1989;16:325327.

    • Search Google Scholar
    • Export Citation
  • 129

    Arnott SJ, Duncan W, Gignoux M. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 1998;41:579583.

    • Search Google Scholar
    • Export Citation
  • 130

    Sur RK, Donde B, Levin VC, Mannell A. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1998;40:447453.

    • Search Google Scholar
    • Export Citation
  • 131

    Gaspar LE, Qian C, Kocha WI. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report. Int J Radiat Oncol Biol Phys 1997;37:593599.

    • Search Google Scholar
    • Export Citation
  • 132

    Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:41104117.

  • 133

    Cooper JS, Guo MD, Herskovic A. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:16231627.

    • Search Google Scholar
    • Export Citation
  • 134

    Minsky BD, Pajak TF, Ginsberg RJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:11671174.

    • Search Google Scholar
    • Export Citation
  • 135

    Li QQ, Liu MZ, Hu YH. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus 2010;23:253259.

    • Search Google Scholar
    • Export Citation
  • 136

    Ruppert BN, Watkins JM, Shirai K. Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol 2010;33:346352.

    • Search Google Scholar
    • Export Citation
  • 137

    Gwynne S, Hurt C, Evans M. Definitive chemoradiation for oesophageal cancer - a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol) 2011;23:182188.

    • Search Google Scholar
    • Export Citation
  • 138

    Conroy T, Yataghene Y, Etienne PL. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer 2010;103:13491355.

    • Search Google Scholar
    • Export Citation
  • 139

    Meerten EV, van Rij C, Tesselaar ME. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract e14508.

    • Search Google Scholar
    • Export Citation
  • 140

    Iyer R, Wilkinson N, Demmy T, Javle M. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol 2004;11:665673.

    • Search Google Scholar
    • Export Citation
  • 141

    Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538543.

    • Search Google Scholar
    • Export Citation
  • 142

    Fiorica F, Di Bona D, Schepis F. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925930.

    • Search Google Scholar
    • Export Citation
  • 143

    Cen P, Correa AM, Le JH. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus 2009;22:3241. [Erratum in Dis Esophagus 2009;22:289.]

    • Search Google Scholar
    • Export Citation
  • 144

    Gebski V, Burmeister B, Smithers BM. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226234.

    • Search Google Scholar
    • Export Citation
  • 145

    Swisher SG, Hofstetter W, Komaki R. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg 2010;90:892898; discussion 898–899.

    • Search Google Scholar
    • Export Citation
  • 146

    Stahl M, Walz MK, Stuschke M. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851856.

    • Search Google Scholar
    • Export Citation
  • 147

    Schnirer II, Komaki R, Yao JC. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 2001;24:9195.

    • Search Google Scholar
    • Export Citation
  • 148

    Kleinberg L, Knisely JP, Heitmiller R. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003;56:328334.

    • Search Google Scholar
    • Export Citation
  • 149

    Khushalani NI, Leichman CG, Proulx G. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002;20:28442850.

    • Search Google Scholar
    • Export Citation
  • 150

    Meluch AA, Greco FA, Gray JR. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003;9:251260.

    • Search Google Scholar
    • Export Citation
  • 151

    Urba SG, Orringer MB, Ianettonni M. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98:21772183.

    • Search Google Scholar
    • Export Citation
  • 152

    Ajani JA, Walsh G, Komaki R. Preoperative induction of CPT- and11 cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004;100:23472354.

    • Search Google Scholar
    • Export Citation
  • 153

    Liao Z, Zhang Z, Jin J. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 2004;60:14841493.

    • Search Google Scholar
    • Export Citation
  • 154

    Pasini F, de Manzoni G, Pedrazzani C. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005;16:11331139.

    • Search Google Scholar
    • Export Citation
  • 155

    Tew WP, Minsky B, Bains M. Phase II trial of preoperative combined modality therapy for esophageal carcinoma: induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy [abstract]. J Clin Oncol 2005(Suppl 1);23:Abstract 4017.

    • Search Google Scholar
    • Export Citation
  • 156

    van Meerten E, Muller K, Tilanus HW. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006;94:13891394.

    • Search Google Scholar
    • Export Citation
  • 157

    Hihara J, Yoshida K, Hamai Y. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res 2007;27:25972603.

    • Search Google Scholar
    • Export Citation
  • 158

    Lorenzen S, Brucher B, Zimmermann F. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer 2008;99:10201026.

    • Search Google Scholar
    • Export Citation
  • 159

    Rivera F, Galan M, Tabernero J. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys 2009;75:14301436.

    • Search Google Scholar
    • Export Citation
  • 160

    Ruhstaller T, Widmer L, Schuller JC. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol 2009;20:15221528.

    • Search Google Scholar
    • Export Citation
  • 161

    Sharma R, Yang GY, Nava HR. A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract e15619.

    • Search Google Scholar
    • Export Citation
  • 162

    Zemanova M, Petruzelka L, Pazdro A. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Dis Esophagus 2010;23:160167.

    • Search Google Scholar
    • Export Citation
  • 163

    Czito BG, Kelsey CR, Hurwitz HI. A phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2007;67:10021007.

    • Search Google Scholar
    • Export Citation
  • 164

    Spigel DR, Greco FA, Meluch AA. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 2010;28:22132219.

    • Search Google Scholar
    • Export Citation
  • 165

    Nygaard K, Hagen S, Hansen HS. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:11041109.

    • Search Google Scholar
    • Export Citation
  • 166

    Walsh TN, Noonan N, Hollywood D. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462467.

    • Search Google Scholar
    • Export Citation
  • 167

    Bosset JF, Gignoux M, Triboulet JP. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161167.

    • Search Google Scholar
    • Export Citation
  • 168

    Ajani JA, Komaki R, Putnam JB. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001;92:279286.

    • Search Google Scholar
    • Export Citation
  • 169

    Urba SG, Orringer MB, Turrisi A. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305313.

    • Search Google Scholar
    • Export Citation
  • 170

    Bains MS, Stojadinovic A, Minsky B. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg 2002;124:270277.

    • Search Google Scholar
    • Export Citation
  • 171

    Kaklamanos IG, Walker GR, Ferry K. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754761.

    • Search Google Scholar
    • Export Citation
  • 172

    Burmeister BH, Smithers BM, Gebski V. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659668.

    • Search Google Scholar
    • Export Citation
  • 173

    Kleinberg L, Powell ME, Forastiere AA. Survival outcome of E1201: an Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4532.

    • Search Google Scholar
    • Export Citation
  • 174

    Gaast AV, van Hagen P, Hulshof M. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 4004.

    • Search Google Scholar
    • Export Citation
  • 175

    Mariette C, Seitz JF, Maillard E. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901 [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 4005.

    • Search Google Scholar
    • Export Citation
  • 176

    Stahl M, Stuschke M, Lehmann N. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:23102317.

    • Search Google Scholar
    • Export Citation
  • 177

    Bedenne L, Michel P, Bouche O. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:11601168.

    • Search Google Scholar
    • Export Citation
  • 178

    Stahl M, Wilke H, Lehmann N. Long-term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous cell carcinoma (LA-SCC) of the esophagus [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4530.

    • Search Google Scholar
    • Export Citation
  • 179

    Bedard EL, Inculet RI, Malthaner RA. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer 2001;91:24232430.

    • Search Google Scholar
    • Export Citation
  • 180

    Rice TW, Adelstein DJ, Chidel MA. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg 2003;126:15901596.

    • Search Google Scholar
    • Export Citation
  • 181

    Adelstein DJ, Rice TW, Rybicki LA. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol 2009;4:12641269.

    • Search Google Scholar
    • Export Citation
  • 182

    Macdonald JS, Smalley SR, Benedetti J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725730.

    • Search Google Scholar
    • Export Citation
  • 183

    Macdonald JS, Benedetti J, Smalley S. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008) [abstract]. J Clin Oncol 2009(Suppl 1);27:Abstract 4515.

    • Search Google Scholar
    • Export Citation
  • 184

    Kelsen DP, Ginsberg R, Pajak TF. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:19791984.

    • Search Google Scholar
    • Export Citation
  • 185

    Kelsen DP, Winter KA, Gunderson LL. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:37193725.

    • Search Google Scholar
    • Export Citation
  • 186

    Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:17271733.

    • Search Google Scholar
    • Export Citation
  • 187

    Allum WH, Stenning SP, Bancewicz J. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:50625067.

    • Search Google Scholar
    • Export Citation
  • 188

    Boige V, Pignon J, Saint-Aubert B. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4510.

    • Search Google Scholar
    • Export Citation
  • 189

    Thirion PG, Michiels S, Le Maitre A. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 4512.

    • Search Google Scholar
    • Export Citation
  • 190

    Homs MY, v d Gaast A, Siersema PD. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev 2006:CD004063.

    • Search Google Scholar
    • Export Citation
  • 191

    Shah MA, Schwartz GK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol 2004;31:574587.

  • 192

    Leichman L, Berry BT. Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol 1991;18:6472.

  • 193

    Muhr-Wilkenshoff F, Hinkelbein W, Ohnesorge I. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis 2003;18:330334.

    • Search Google Scholar
    • Export Citation
  • 194

    Enzinger PC, Kulke MH, Clark JW. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005;50:22182223.

    • Search Google Scholar
    • Export Citation
  • 195

    Burkart C, Bokemeyer C, Klump B. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res 2007;27:28452848.

    • Search Google Scholar
    • Export Citation
  • 196

    Muro K, Hamaguchi T, Ohtsu A. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955959.

    • Search Google Scholar
    • Export Citation
  • 197

    Albertsson M, Johansson B, Friesland S. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol 2007;24:407412.

    • Search Google Scholar
    • Export Citation
  • 198

    Ajani JA, Ilson DH, Daugherty K. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:10861091.

    • Search Google Scholar
    • Export Citation
  • 199

    Mauer AM, Kraut EH, Krauss SA. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005;16:13201325.

    • Search Google Scholar
    • Export Citation
  • 200

    Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007;18:898902.

    • Search Google Scholar
    • Export Citation
  • 201

    Harstrick A, Bokemeyer C, Preusser P. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol 1992;29:321322.

    • Search Google Scholar
    • Export Citation
  • 202

    Ilson DH, Ajani J, Bhalla K. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:18261834.

    • Search Google Scholar
    • Export Citation
  • 203

    Ilson DH, Forastiere A, Arquette M. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316323.

    • Search Google Scholar
    • Export Citation
  • 204

    Petrasch S, Welt A, Reinacher A. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998;78:511514.

    • Search Google Scholar
    • Export Citation
  • 205

    Ajani JA, Fodor MB, Tjulandin SA. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:56605667.

    • Search Google Scholar
    • Export Citation
  • 206

    Van Cutsem E, Moiseyenko VM, Tjulandin S. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:49914997.

    • Search Google Scholar
    • Export Citation
  • 207

    Kim JY, Do YR, Park KU. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol 2010;66:3136.

    • Search Google Scholar
    • Export Citation
  • 208

    Al-Batran SE, Hartmann JT, Hofheinz R. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008;19:18821887.

    • Search Google Scholar
    • Export Citation
  • 209

    Shankaran V, Mulcahy MF, Hochster HS. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: preliminary results of a phase II study [abstract]. Presented at: 2009 Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 47.

    • Search Google Scholar
    • Export Citation
  • 210

    Overman MJ, Kazmi SM, Jhamb J. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 2010;116:14461453.

    • Search Google Scholar
    • Export Citation
  • 211

    Tebbutt NC, Cummins MM, Sourjina T. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 2010;102:475481.

    • Search Google Scholar
    • Export Citation
  • 212

    Arnold D, Thuss-Patience PC, Stein A. Docetaxel, oxaliplatin, and capecitabine (TEX regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): results from a phase II trial of the German AIO group [abstract]. J Clin Oncol 2010;28:Abstract 4099.

    • Search Google Scholar
    • Export Citation
  • 213

    Shah MA, Shibata S, Stoller RG. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE) [abstract]. J Clin Oncol 2010;28:Abstract 4014.

    • Search Google Scholar
    • Export Citation
  • 214

    Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004;18:2225.

  • 215

    Ross P, Nicolson M, Cunningham D. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:19962004.

    • Search Google Scholar
    • Export Citation
  • 216

    Millar J, Scullin P, Morrison A. Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer 2005;93:11121116.

    • Search Google Scholar
    • Export Citation
  • 217

    Urba SG, Chansky K, VanVeldhuizen PJ. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group study. Invest New Drugs 2004;22:9197.

    • Search Google Scholar
    • Export Citation
  • 218

    Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006;107:221231.

  • 219

    Cunningham D, Starling N, Rao S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:3646.

  • 220

    Assersohn L, Brown G, Cunningham D. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004;15:6469.

    • Search Google Scholar
    • Export Citation
  • 221

    Wolff K, Wein A, Reulbach U. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs 2009;20:165173.

    • Search Google Scholar
    • Export Citation
  • 222

    Dank M, Zaluski J, Barone C. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:14501457.

    • Search Google Scholar
    • Export Citation
  • 223

    Samalin E, Afchain P, Thezenas S. Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Gastroenterol Clin Biol, in press.

    • Search Google Scholar
    • Export Citation
  • 224

    Leary A, Assersohn L, Cunningham D. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol 2009;64:455462.

    • Search Google Scholar
    • Export Citation
  • 225

    Moehler M, Kanzler S, Geissler M. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010;21:7177.

    • Search Google Scholar
    • Export Citation
  • 226

    Burtness B, Gibson M, Egleston B. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol 2009;20:12421248.

    • Search Google Scholar
    • Export Citation
  • 227

    Lustberg MB, Bekaii-Saab T, Young D. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol 2010;5:713718.

    • Search Google Scholar
    • Export Citation
  • 228

    El-Rayes BF, Shields A, Zalupski M. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 2004;15:960965.

  • 229

    Al-Batran SE, Hartmann JT, Probst S. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:14351442.

    • Search Google Scholar
    • Export Citation
  • 230

    Pipp M, Mulkerin D, Warren D. A phase II trial of gemcitabine and 5-fluoruracil in advanced esophageal cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:Abstract 630.

    • Search Google Scholar
    • Export Citation
  • 231

    Morgan-Meadows S, Mulkerin D, Berlin JD. A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology 2005;69:130134.

    • Search Google Scholar
    • Export Citation
  • 232

    Homs MY, Voest EE, Siersema PD. Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs 2009;14:329339.

  • 233

    De Vita F, Orditura M, Innocente R. A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 4546.

    • Search Google Scholar
    • Export Citation
  • 234

    Gold PJ, Goldman B, Iqbal S. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group Study [abstract]. J Clin Oncol 2008;26(Suppl 1):Abtract 4536.

    • Search Google Scholar
    • Export Citation
  • 235

    Ku GY, Shah MA, Tang LH. Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 15580.

    • Search Google Scholar
    • Export Citation
  • 236

    Lorenzen S, Schuster T, Porschen R. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:16671673.

    • Search Google Scholar
    • Export Citation
  • 237

    Pinto C, Di Fabio F, Siena S. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510517.

    • Search Google Scholar
    • Export Citation
  • 238

    Enzinger PC, Burtness B, Hollis D. CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 4006.

    • Search Google Scholar
    • Export Citation
  • 239

    Dragovich T, McCoy S, Fenoglio-Preiser CM. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:49224927.

    • Search Google Scholar
    • Export Citation
  • 240

    Wainberg ZA, Lin L, DiCarlo B. Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ) [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 4050.

    • Search Google Scholar
    • Export Citation
  • 241

    Ilson DH, Kelsen D, Shah M. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2011;117:14091414.

    • Search Google Scholar
    • Export Citation
  • 242

    Enzinger PC, Ryan DP, Regan EM. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4552.

    • Search Google Scholar
    • Export Citation
  • 243

    Kelsen D, Jhawer M, Ilson D. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 4512.

    • Search Google Scholar
    • Export Citation
  • 244

    de Graaf GW, Ayantunde AA, Parsons SL. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007;33:988992.

  • 245

    Rosenbaum S, Stergar H, Antoch G. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdominal Imaging 2006;31:2535.

  • 246

    Munden RF, Macapinlac HA, Erasmus JJ. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. J Thorac Imaging 2006;21:137145.

    • Search Google Scholar
    • Export Citation
  • 247

    van Westreenen HL, Westerterp M, Bossuyt PM. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004;22:38053812.

    • Search Google Scholar
    • Export Citation
  • 248

    Flamen P, Lerut A, Van Cutsem E. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:32023210.

    • Search Google Scholar
    • Export Citation
  • 249

    Flamen P, Lerut T, Haustermans K. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging 2004;48:96108.

    • Search Google Scholar
    • Export Citation
  • 250

    Cerfolio RJ, Bryant AS, Ohja B. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005;129:12321241.

    • Search Google Scholar
    • Export Citation
  • 251

    Lordick F, Ott K, Krause BJ. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797805.

    • Search Google Scholar
    • Export Citation
  • 252

    Lordick F, Meyer Zum Bueschenfelde C, Herrmann K. PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): the MUNICON-II study [abstract]. J Clin Oncol 2011;29(Suppl 4):Abstract 3.

    • Search Google Scholar
    • Export Citation
  • 253

    Flamen P, Van Cutsem E, Lerut A. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361368.

    • Search Google Scholar
    • Export Citation
  • 254

    Swisher SG, Erasmus J, Maish M. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:17761785.

    • Search Google Scholar
    • Export Citation
  • 255

    Song SY, Kim JH, Ryu JS. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005;63:10531059.

    • Search Google Scholar
    • Export Citation
  • 256

    Levine EA, Farmer MR, Clark P. Predictive value of 18-fluorodeoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006;243:472478.

    • Search Google Scholar
    • Export Citation
  • 257

    Konski AA, Cheng JD, Goldberg M. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:358363.

    • Search Google Scholar
    • Export Citation
  • 258

    Monjazeb AM, Riedlinger G, Aklilu M. Outcomes of patients with esophageal cancer staged with [(1)F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 2010;28:47144721.

    • Search Google Scholar
    • Export Citation
  • 259

    Gillham CM, Lucey JA, Keogan M. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:11741179.

    • Search Google Scholar
    • Export Citation
  • 260

    Smithers BM, Couper GC, Thomas JM. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 2008;21:151158.

    • Search Google Scholar
    • Export Citation
  • 261

    Klaeser B, Nitzsche E, Schuller JC. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multicenter trial (SAKK 75/02). Onkologie 2009;32:724730.

    • Search Google Scholar
    • Export Citation
  • 262

    Vallbohmer D, Holscher AH, Dietlein M. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009;250:888894.

    • Search Google Scholar
    • Export Citation
  • 263

    Malik V, Lucey JA, Duffy GJ. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 2010;51:18631869.

    • Search Google Scholar
    • Export Citation
  • 264

    van Heijl M, Omloo JM, van Berge Henegouwen MI. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 2011;253:5663.

    • Search Google Scholar
    • Export Citation
  • 265

    Colasanto JM, Prasad P, Nash MA. Nutritional support of patients undergoing radiation therapy for head and neck cancer. Oncology (Williston Park) 2005;19:371379.

    • Search Google Scholar
    • Export Citation
  • 266

    Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649655.

  • 267

    Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187193.

  • 268

    Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000;355:15881596.

    • Search Google Scholar
    • Export Citation
  • 269

    Jager E, Heike M, Bernhard H. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14:22742279.

    • Search Google Scholar
    • Export Citation
  • 270

    O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989;63:10261030.

    • Search Google Scholar
    • Export Citation
  • 271

    Homs MY, Steyerberg EW, Eijkenboom WM. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004;364:14971504.

    • Search Google Scholar
    • Export Citation
  • 272

    Shin JH, Song HY, Kim JH. Comparison of temporary and permanent stent placement with concurrent radiation therapy in patients with esophageal carcinoma. J Vasc Interv Radiol 2005;16:6774.

    • Search Google Scholar
    • Export Citation
  • 273

    Ross WA, Alkassab F, Lynch PM. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest Endosc 2007;65:7076.